An Assessment of the Occurrence of Hormone Deficiency in Patients With Empty Sella
(Partial) Empty Sella - Incidental Finding or the Cause of Hormonal Dysregulation?
The goal of this prospective study is to analyse the hormonal components in the blood of
patients that were diagnosed with empty sella. Hereby we only take the hormones into
consideration that are produced by the pituitary gland and/or are influenced by it due to
positive/negative feedback. These are GH, ACTH, TSH, FSH, LH, PRL, oxytocine, ADH but also
IGF-1, estradiol, testosteron, F4 and cortisol. The purpose is to see if abnormalities of the
blook levels can be explained by the absence/shrinking of the pituitary gland. During this
study, there will be a blood draw twice. The reason is to avoid wrong positive and negative
results. Together with the second blood draw, there will be an insuline tolerance test in all
patients. MRI will only be done if the last taken image is more than two years old or if the
MRI was not taken with main focus on the pituitary gland.
The proportion of patients that have hormone deficiency
Study Arms / Comparison Groups
Patients above the age of 18 years
Description: In the context of this study, we will take two blood samples. In addition to the second blood sample, an insulin tolerance test (ITT) is also performed, even if the result of the blood values is normal.
MRI will only be performed if the previous imaging was done more than two years ago or when the quality of the MRI was not good enough to measure the volume of the pituitary gland.
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
October 14, 2019
Primary Completion Date
- Patients that were diagnosed with an (partial) empty sella detected by MRI or CT of
the brain have been included in this study. Whenever the MRI or CT scan was performed
more than two years ago, a new MRI scan was required.
- Children (patients less than 18 years) and patients with earlier diagnosed carcinomas
of the brain as well as patients with secondary empty sella (antecedents of radiation,
pharmacological treatment of pituitary adenomas, traumatic head injury and surgery of
the pituitary gland as well as the central nervous system) were not included.